Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03651505 · ClinicalTrials.gov registry record
X-linked Hypophosphatemia Disease Monitoring Program
A clinical trial of X-linked Hypophosphatemia and Hypophosphatemic Rickets, sponsored by Ultragenyx Pharmaceutical.
- Active
- Registry status
- 782
- Enrollment target
- 20
- Study locations
NCT03651505 is a study of X-linked Hypophosphatemia and Hypophosphatemic Rickets that is active but no longer recruiting, run by Ultragenyx Pharmaceutical. The registered enrollment target is 782 participants, above the 18-participant average among 5 other X-linked Hypophosphatemia trials with a reported enrollment target (4244% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT03651505, a study of X-linked Hypophosphatemia and Hypophosphatemic Rickets, is active but no longer recruiting, sponsored by Ultragenyx Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- 782 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Rady Children's Hospital San Diego - San Diego
- University of California San Francisco - San Francisco
Ohio
- Cincinnati Children's Hospital - Cincinnati
- Nationwide Children's Hospital - Columbus
- The Ohio State University Wexner Medical Center - Columbus
Tennessee
- Vanderbilt University - Department of Medicine - Nashville
- Vanderbilt University - Department of Pediatrics - Nashville
Texas
- Houston Methodist Research Institute - Houston
- University of Texas, Health Science Center - Houston
Alabama
- Children's Hospital of Alabama - Birmingham
Colorado
- Children's Hospital of Colorado - Aurora
Connecticut
- Yale University School of Medicine - New Haven
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 782 participants |
| Start Date | 2018-07-16 |
| Est. Completion | 2032-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03651505
The ClinicalTrials.gov registry entry for NCT03651505 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 782 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 18-participant average among 5 other X-linked Hypophosphatemia trials with a reported enrollment target (4244% higher). The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with X-linked Hypophosphatemia appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT03651505 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT03651505 about?
NCT03651505 is a clinical study titled "X-linked Hypophosphatemia Disease Monitoring Program". The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.
What is the current status of trial NCT03651505?
This trial is currently active not recruiting. The enrollment target is 782 participants. The study started on 2018-07-16. Estimated completion is 2032-12.
What conditions does trial NCT03651505 study?
This clinical trial studies the following conditions: X-linked Hypophosphatemia, Hypophosphatemic Rickets.
What interventions are being tested in trial NCT03651505?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT03651505?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03651505 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for X-linked Hypophosphatemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
RECRUITING · Phase 1
-
Calcitriol Monotherapy for X-Linked Hypophosphatemia
ACTIVE NOT RECRUITING · Early Phase 1
-
Examining the Effect of Burosumab on Muscle Function
COMPLETED · Phase 4
-
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
COMPLETED · Phase 1
-
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.